



Transcription Factors in Breast Cancer

Guest Editor:

Dr. Sarah Walker

Department of Molecular,
Cellular, and Biomedical
Sciences, University of New
Hampshire, Durham, NH 03824,
USA

Deadline for manuscript
submissions:

31 October 2024

Message from the Guest Editor

Dear Colleagues,

Breast cancers are generally identified and treated based on ER, PR, and Her2 expression status. ER and PR modulate a transcription program promoting tumor proliferation, whereas Her2 activates a signaling cascade, leading to the activation of a variety of transcription factors. Moreover, triple-negative breast cancers lack these drivers of breast cancer and often have an activation of different transcription factors that regulate many genes promoting proliferation, metastasis and resistance to chemotherapy. Understanding which transcription factors are active in breast cancers, TNBC or others, may provide new avenues for treating breast cancer. Therefore, this Special Issue will focus on various transcription factors that are activated in breast cancer, looking at the signaling pathways associated with the transcription factors, understanding the gene signatures regulated by these transcription factors, or identifying molecules to target these transcription factors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)